Major AIDS forum gets down to work amid surge of good news

July 17, 2011 by Richard Ingham

A global medical forum on AIDS got down to business on Sunday for four days of debate on powerful new weapons to combat a pandemic that in 30 years has claimed as many lives as a World War.

Held every two years, the meeting is taking place in Rome amid a flurry of startlingly good news from field trials, prompting some veterans to talk of a in the AIDS story.

"This conference could well be a turnaround," Elly Katabira, president of the International AIDS Society (IAS) staging the meeting, told a press conference.

"The results presented this week could prove today as important as the antiretrovirals breakthroughs of the mid-nineties."

The cause for the excitement is scientific proof that the famous "cocktail" of drugs used to treat people with the can also be used to prevent in others.

The conference will hear the latest data from a trial conducted among "sero-discordant" in Africa, meaning couples in which one partner had been tested positive HIV while the other was uninfected.

The risk of HIV infection fell by 96 percent when the infected partner started early use of daily antiretrovirals.

Evidence of this kind -- supported by several other trials in which treatment drugs were used for prevention -- points to new ways to stop the relentless rise in new HIV infections, say some experts.

Thirty million people have been killed by AIDS since the disease first came to light in June 1981. In 2009, more than 33 million people were living with HIV and 2.6 million people became newly infected, according to UNAIDS.

"We have the proof: this really is a landmark moment in prevention, it is a revolution in a sense," said Stefano Vella, research director at Italy's Superior Institute of Health.

Asked if the end of the was in sight, Chris Beyrer, a professor at the John Hopkins Bloomberg School of Public Health in Baltimore, Maryland, said "the chances just got tremendously better."

But funding and turning the scientific evidence into action on the ground were the key, he cautioned.

AIDS spending today is around $16 billion (11 billion euros) annually, compared with current needs estimated at 24 billion, said Michel Sidibe, executive director of UNAIDS.

"Treatment as prevention could pay for itself in about a decade," Jean-Paul Moatti, an economics professor at France's University of the Mediterranean in Marseille, southern France, told AFP.

"Countries would have lower health costs and better productivity because fewer people fall sick."

The conference gathers 5,500 specialists, ranging from virologists to pharmacologists and disease trackers.

It is staged once every two years by the IAS, which also organises the International Conference, a bigger event that touches on the pandemic's many social dimensions.

Other trials to be discussed in Rome will look at the effectiveness of giving uninfected people HIV drugs -- an approach called "pre-exposure prophylaxis," or PrEP -- and progress to encourage circumcision in African men. Male circumcision has been found to more than halve the risk of HIV infection for men.

Explore further: AIDS: HIV drugs boost prevention hopes

Related Stories

AIDS: HIV drugs boost prevention hopes

July 13, 2011

Heterosexuals who take daily AIDS drugs reduce the risk of being infected by the human immunodeficiency virus (HIV) by nearly two-thirds, ground-breaking studies said on Wednesday.

Roll out treatment as prevention now to stop HIV and AIDS

July 14, 2011

The Lancet, a leading global medical journal, published an editorial comment today that emphasizes the critical role of expanding access to HIV treatment under a "Treatment as Prevention" strategy to stop the HIV pandemic.

Recommended for you

Targeting HIV in semen to shut down AIDS

August 18, 2015

There may be two new ways to fight AIDS—using a heat shock protein or a small molecule - to attack fibrils in semen associated with the human immunodeficiency virus (HIV) during the initial phases of infection, according ...

Vitamin D status related to immune response to HIV-1

June 15, 2015

Vitamin D plays an important part in the human immune response and deficiency can leave individuals less able to fight infections like HIV-1. Now an international team of researchers has found that high-dose vitamin D supplementation ...

HVTN 505 vaccine induced antibodies nonspecific for HIV

July 30, 2015

A study by researchers at the National Institute of Allergy and Infectious Diseases and Duke University helps explain why the candidate vaccine used in the HVTN 505 clinical trial was not protective against HIV infection ...

Why HIV's cloak has a long tail

June 2, 2015

Virologists at Emory University School of Medicine, Yerkes National Primate Research Center, and Children's Healthcare of Atlanta have uncovered a critical detail explaining how HIV assembles its infectious yet stealthy clothing.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.